Pam3CSK4 TFA
Based on 22 publication(s) in Google Scholar
Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.89%
- CAS. Nr.: 112208-01-2
- Formel: C87H159F9N10O19S
- Molecular Weight:1852.30
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pam3CSK4 TFA
More- Nat Immunol. 2025 Oct;26(10):1660-1672. [Abstract]
- J Adv Res. 2026 May 4:S2090-1232(26)00378-4. [Abstract]
- Mol Biomed. 2026 Jun 23;7(1):94. [Abstract]
- J Control Release. 2026 Mar 10:391:114645. [Abstract]
- Phytomedicine. 2025 Jun:141:156705. [Abstract]
- J Pharm Anal. 2025 Jan;15(1):101054. [Abstract]
- Chin Herb Med. 2024 Apr 30;16(3):422-434. [Abstract]
- NPJ Sci Food. 2026 Jan 23;10(1):73. [Abstract]
- Sci China Life Sci. 2024 Dec;67(12):2664-2677. [Abstract]
- Food Res Int. 2026 Feb 6.
- Atherosclerosis. 2026 Jan 26:414:120648. [Abstract]
- Int Immunopharmacol. 2022 Dec;113(Pt A):109312. [Abstract]
- Int Immunopharmacol. 2022 May:106:108613. [Abstract]
- PLoS Pathog. 2024 Nov 5;20(11):e1012614. [Abstract]
- Sci Rep. 2023 Nov 9;13(1):19440. [Abstract]
- Sci Rep. 2022 Oct 12;12(1):17058. [Abstract]
- Antiviral Res. 2022 Jul:203:105346. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2026 Jan 19. [Abstract]
- J Funct Foods. 2026 May 30;142:107364.
- Mol Immunol. 2021 Feb;130:85-95. [Abstract]
- Microbes Infect. 2024 Jan-Feb;26(1-2):105244. [Abstract]
- Biochem Biophys Res Commun. 2024 Apr 16:704:149661. [Abstract]
Customer Validation & Images
-
ELISA
-
WB
-
WB
-
WB
-
WB
Biologische Aktivität
|
TLR1 |
TLR2 |
Pam3CSK4 is a TLR1/2 heterodimer recognises triacylated lipopeptides[1].
Pam3CSK4 (1 μg/mL) enhances the antibacterial functions of granulocyte macrophage-colony stimulating factor (GM-CSF) induced neutrophils to Methicillin-resistant Staphylococcus aureus (MRSA)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2tm1Kir/J (TLR2 -deficient) mice[3]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneally (i.p.); once a day for 9 days
-
Result:After repeated administration from postnatal day (PND3) to PND11, brain weight was decreased compared with endotoxin-free saline-treated animals at PND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at PND12.
Chemical Information
-
CAS. Nr. 112208-01-2
-
Appearance Solid
-
Molecular Weight 1852.30
-
Formel C87H159F9N10O19S
-
Color White to off-white
-
Synonyms
Pam3Cys-Ser-(Lys)4 TFA
-
Sequence
Pal-Cys-Ser-Lys-Lys-Lys-Lys
-
Sequence Shortening
Pal-CSKKKK
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
Nat Immunol
Delaying pyroptosis with an AI-screened gasdermin D pore blocker mitigates inflammatory response. [Abstract]2025 Oct;26(10):1660-1672. PMID: 40954252
Pam3CSK4 TFA purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Oct;26(10):1660-1672. [Abstract]
Pam3CSK4 (Pam3; 1 µg/mL; 12 h). ELISA of secreted from wild-type BMDCs treated with PBS, BFP, GSDMD-NT, SK56, SK56 + GSDMD-NT, oxPAPC, SK56 + oxPAPC or pyroptotic cytomembrane fragments from mouse wild-type or Gsdmd−/− BMDMs as in c (NCF, PCF, PCF + SK56, PCFGsdmd−/−, PCFGsdmd−/− + SK56), treated or not treated with Pam3 for 12 h.
-
J Adv Res
4-Octyl itaconate-induced Nrf2 nuclear translocation mitigates Caspase-11-dependent noncanonical macrophage pyroptosis and acute lung injury. [Abstract]2026 May 4:S2090-1232(26)00378-4. PMID: 42092588 -
Mol Biomed
Death-associated protein kinase 2 (DAPK2) propagates endoplasmic reticulum stress in macrophages to worsen sepsis through HSPA5-IRE1α axis. [Abstract]2026 Jun 23;7(1):94. PMID: 42334722 -
J Control Release
Development of a lymph node-homing peptide vaccine targeting C-C chemokine receptor 7-positive dendritic cells with enhanced antitumor immunity. [Abstract]2026 Mar 10:391:114645. PMID: 41580130 -
Phytomedicine
Gusongan capsule enhances osteogenic differentiation to mitigate bone loss in ovariectomized rats via the TLR2/NF-κB pathway. [Abstract]2025 Jun:141:156705. PMID: 40215821 -
J Pharm Anal
Oxymatrine, a novel TLR2 agonist, promotes megakaryopoiesis and thrombopoiesis through the STING/NF-κB pathway. [Abstract]2025 Jan;15(1):101054. PMID: 39906691
Pam3CSK4 TFA purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Jan;15(1):101054. [Abstract]
Representative immunoblot images after the treatment of Oxymatrine (40 μM), Pam3CSK4 (3 μM), for five days.
-
Chin Herb Med
Amplifying protection against acute lung injury: Targeting both inflammasome and cGAS-STING pathway by Lonicerae Japonicae Flos-Forsythiae Fructus drug pair. [Abstract]2024 Apr 30;16(3):422-434. PMID: 39072201
Pam3CSK4 TFA purchased from MedChemExpress. Usage Cited in: Chin Herb Med. 2024 Apr 30;16(3):422-434. [Abstract]
Pam3CSK4 (400 ng/mL; 4 h). Relative protein expression levels of Casp-1 p20 in BMDMs.
Pam3CSK4 TFA purchased from MedChemExpress. Usage Cited in: Chin Herb Med. 2024 Apr 30;16(3):422-434. [Abstract]
Pam3CSK4 (400 ng/mL; 4 h). LPS-primed BMDMs with LJF, FF, or vehicle for 1 h and then stimulated with Pam3CSK4-primed BMDMs were pretreated with LJF, FF, or vehicle and then stimulated with transfected LPS. Activated caspase-1 (P20) and cleaved IL-1β (P17) in culture supernatants (SN) of BMDMs and NLRP3, ASC, pro-caspase-1(p45), pro-IL-1β in whole-cell lysates (WCL) by western blot analyses.
-
NPJ Sci Food
Computational-experimental study reveals direct target and bioactives of Ajania fruticulosa against NAFLD via TLR2/NF-κB/PPAR-γ signaling. [Abstract]2026 Jan 23;10(1):73. PMID: 41577727 -
Sci China Life Sci
Targeting STING oligomerization with licochalcone D ameliorates STING-driven inflammatory diseases. [Abstract]2024 Dec;67(12):2664-2677. PMID: 39190126 -
-
Atherosclerosis
Isolinderalactone alleviates atherosclerosis by inhibiting NLRP3 inflammasome activation and inflammatory response in macrophages. [Abstract]2026 Jan 26:414:120648. PMID: 41759391 -
Int Immunopharmacol
Resibufogenin, one of bufadienolides in toad venom, suppresses LPS-induced inflammation via inhibiting NF-κB and AP-1 pathways. [Abstract]2022 Dec;113(Pt A):109312. PMID: 36252491 -
Int Immunopharmacol
SIX1 attenuates inflammation and rheumatoid arthritis by silencing MyD88-dependent TLR1/2 signaling. [Abstract]2022 May:106:108613. PMID: 35180623 -
PLoS Pathog
2024 Nov 5;20(11):e1012614. PMID: 39499730
Pam3CSK4 TFA purchased from MedChemExpress. Usage Cited in: PLoS Pathog. 2024 Nov 5;20(11):e1012614. [Abstract]
Pam3CSK4 (1 µg/mL; 12 h). Irg1 mRNA expression in neutrophils, pooled from three independent experiments.
-
Sci Rep
Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer. [Abstract]2023 Nov 9;13(1):19440. PMID: 37945630 -
Sci Rep
A comparative study of spike protein of SARS-CoV-2 and its variant Omicron (B.1.1.529) on some immune characteristics. [Abstract]2022 Oct 12;12(1):17058. PMID: 36224298 -
Antiviral Res
TLR2-mediated mucosal immune priming boosts anti-rhabdoviral immunity in early vertebrates. [Abstract]2022 Jul:203:105346. PMID: 35605698 -
Naunyn Schmiedebergs Arch Pharmacol
Quercetin inhibits microglial pyroptosis following intracerebral hemorrhage via the TLR2/MyD88/NF-κB signaling pathway. [Abstract]2026 Jan 19. PMID: 41549176 -
-
Mol Immunol
Impact of knockdown LincRNA-Cox2 on apoptosis of macrophage infected with Bacillus Calmette-Guérin. [Abstract]2021 Feb;130:85-95. PMID: 33250268 -
Microbes Infect
Corydalis Saxicola Bunting Total Alkaloid Eliminates Porphyromonas gingivalis strain 33277 Internalized into Macrophages by Inhibition of TLR2. [Abstract]2024 Jan-Feb;26(1-2):105244. PMID: 37914020 -
Biochem Biophys Res Commun
Sequential administration of delta-tocotrienol ameliorates radiation-induced myelosuppression in mice and non-human primates through inducing G-CSF production. [Abstract]2024 Apr 16:704:149661. PMID: 38417343
Lösungsmittel & Löslichkeit
DMSO : 25 mg/mL (13.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 16.67 mg/mL (9.00 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Irvine KL, et al. The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6. Vet Res. 2013 Jul 4;44:50. [Content Brief]
[2]. Chen Y, et al. TLR2 agonist Pam3CSK4 enhances the antibacterial functions of GM-CSF induced neutrophils to methicillin-resistant Staphylococcus aureus. Microb Pathog. 2019 May;130:204-212. [Content Brief]
[3]. Du X, et al. Systemic stimulation of TLR2 impairs neonatal mouse brain development. PLoS One. 2011 May 6;6(5):e19583. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.5399 mL | 2.6993 mL | 5.3987 mL | 13.4967 mL |
| 5 mM | 0.1080 mL | 0.5399 mL | 1.0797 mL | 2.6993 mL | |
| DMSO | 10 mM | 0.0540 mL | 0.2699 mL | 0.5399 mL | 1.3497 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Pam3CSK4 TFA Related Classifications
HY-P1180A Related Classifications
Powered by Bioz